Korean J Gastroenterol.  2017 Jan;69(1):90-91. 10.4166/kjg.2017.69.1.90.

The Phase 3 Trials of Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease

• Park SH

• KMID: 2383439
• DOI: http://doi.org/10.4166/kjg.2017.69.1.90

Abstract

No abstract available.

MeSH Terms

Crohn Disease*
Ustekinumab*
Ustekinumab

Reference

References

1. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016; 14:111–119.

2. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369:1641–1657.

3. Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with metaanalysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2017; 45:3–13.

4. Singh S, Pardi DS. Update on anti-tumor necrosis factor agents in Crohn disease. Gastroenterol Clin North Am. 2014; 43:457–478.

5. Swoger JM, Regueiro M. Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops. Inflamm Bowel Dis. 2014; 20:926–935.

6. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013; 369:711–721.

7. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016; 375:1946–1960.

8. Papp KA, Griffiths CE, Gordon K, et al. Longterm safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013; 168:844–854.

9. Papp K, Gottlieb AB, Naldi L, et al. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015; 14:706–714.

10. Park SH, Yang SK, Park SK, et al. Longterm prognosis of crohn's disease and its temporal change between 1981 and 2012: a hos-pital-based cohort study from Korea. Inflamm Bowel Dis. 2014; 20:488–494.

11. Park SH, Hwang SW, Kwak MS, et al. Longterm outcomes of infliximab treatment in 582 Korean patients with Crohn's disease: a hospital-based cohort study. Dig Dis Sci. 2016; 61:2060–2067.

12. Loftus EV, Augustin M, Bissonnette R, et al. Prevalence of inflammatory bowel disease among patients with psoriasis and incidence of serious infections in this subset: results from the PSOLAR registry. Gastroenterology. 2016; 150(4 Suppl 1):S805.

13. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2014; 63:88–95.